for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Acceleron Pharma Inc

XLRN.OQ

Latest Trade

42.15USD

Change

-1.10(-2.54%)

Volume

99,550

Today's Range

41.99

 - 

43.35

52 Week Range

37.01

 - 

59.06

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
43.25
Open
43.01
Volume
99,550
3M AVG Volume
5.89
Today's High
43.35
Today's Low
41.99
52 Week High
59.06
52 Week Low
37.01
Shares Out (MIL)
52.83
Market Cap (MIL)
2,226.94
Forward P/E
-18.85
Dividend (Yield %)
--

Next Event

Q3 2019 Acceleron Pharma Inc Earnings Release

Latest Developments

More

Acceleron To Discontinue Development Of Ace-083 In Facioscapulohumeral Muscular Dystrophy

Acceleron Receives FDA Orphan Drug Designation For Sotatercept

Acceleron Qtrly Loss Per Share $0.34

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Acceleron Pharma Inc

Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. It has four internally discovered therapeutic candidates that are in clinical trials, which include luspatercept, sotatercept, dalantercept and ACE-083. It offers a platform technology, IntelliTrap. It is also evaluating ACE-1332, a selective TGF-beta antagonist, for treatment of disorders with a fibrotic component, and additional molecules from its IntelliTrap platform for undisclosed therapeutic areas. Dalantercept is designed to treat cancers by inhibiting blood vessel formation by inhibiting signaling through the ALK1 receptor. ACE-083 is designed to promote muscle growth and function in specific, targeted muscles.

Industry

Biotechnology & Drugs

Contact Info

128 Sidney St

+1.617.6499200

http://www.acceleronpharma.com/

Executive Leadership

Francois E. Nader

Independent Chairman of the Board

Habib J. Dable

President, Chief Executive Officer, Director

Kevin F. McLaughlin

Chief Financial Officer, Senior Vice President, Treasurer

John D. Quisel

Executive Vice President, Chief Business Officer, Secretary

Ravindra Kumar

Senior Vice President, Chief Scientific Officer

Key Stats

2.00 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.1K
EPS (USD)

2016

-1.520

2017

-2.680

2018

-2.590

2019(E)

-2.276
Price To Earnings (TTM)
--
Price To Sales (TTM)
59.35
Price To Book (MRQ)
4.45
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-27.76
Return on Equity (TTM)
-26.51

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up